
The Physicians Really Are Healing Themselves, With Ozempic
When Dr. C. Michael Gibson, a cardiologist at Harvard Medical School, goes to heart disease meetings, he can't help noticing a change.
'We will sit around at dinner and halfway through the meal, we will simultaneously push our plates away,' Dr. Gibson said. 'We look at each other and laugh and say, 'You, too?''
They share what is becoming an open secret: They tried for years to control their weight but are now taking the new obesity drugs manufactured by Eli Lilly and Novo Nordisk.
Dr. Robert Califf, the former chief of the Food and Drug Administration, says he hardly recognizes his colleagues. So many are now so thin.
'Looking good,' he says he tells his fellow cardiologists at conferences and meetings.
There are no studies documenting the percentage of doctors taking the drugs. But physicians 'are a good litmus test for drugs that are highly effective,' Dr. Califf said. If doctors who read the papers describing clinical-trial results are rushing to get a new drug, that is an indication that it's really promising.
His colleagues' use of Wegovy and Zepbound reminds him of the use of statins, drugs that lower cholesterol, in their early days. Cardiologists, who were most familiar with the consequences of high cholesterol levels, were among the first to take the drugs in large numbers.
Many newly thin cardiologists and diabetes specialists, like so many of their patients, had risk factors for heart disease. Or their blood sugar was creeping up. Or just the physical strain of carrying excess weight made everyday life burdensome. They say they like their new looks but also their new health and energy. In a way, they feel like members of a club.
Four years ago, Dr. Darren McGuire, a cardiologist at the University of Texas Southwestern, was struggling with obesity and Type 2 diabetes. Then he started taking Ozempic, the Novo Nordisk diabetes drug that is sold under the name Wegovy for obesity. He later switched to Mounjaro, from Eli Lilly, which is sold as Zepbound for obesity.
He lost 30 percent of his weight and got his blood sugar under control. Now, he said, he's 'feeling better than ever.'
He is also struck by the number of colleagues who seem to be using the medications.
'People look pretty different,' said Dr. McGuire, who is on advisory boards for Novo Nordisk and Eli Lilly. 'It is amazing.' He described one prominent diabetes specialist, Dr. John Buse of the University of North Carolina, who 'has shrunk away.'
Not quite, Dr. Buse said. But, he said, 'I lost 25 percent of my body weight and it totally changed my life.' He had struggled with his size since childhood, gaining, losing and then gaining weight again.
When he dieted, he 'would get crazy hungry,' Dr. Buse said. With Wegovy, he said, his weight dropped effortlessly until he reached his goal. Then his appetite returned, which was scary. But instead of regaining pounds, he maintained a consistent weight as he continued to take the drug.
Like other patients, he found that taking the drugs eliminated most of his desire to drink alcohol. Before he started Wegovy, he often would have two or three drinks with dinner. Now he has one, or none.
Dr. Buse, who is a consultant for Novo Nordisk and Eli Lilly, said that he did not often ask people at diabetes meetings if they were taking one of the drugs but that 'there are people who have changed a lot.' He said he would 'bet dollars to doughnuts' that they were on weight-loss medication.
Some cardiologists are still 'in the closet,' Dr. Gibson said.
One is a cardiologist in Boston. She said the person who prescribed Ozempic for her was also a female cardiologist who was taking it. She asked not to be identified because she had told only a few people she was on the drug. She was trying to keep her medical information private, although she suspected that her colleagues might have guessed. She added that she was pretty sure she knew who else was taking one of the drugs.
'Yes, you can definitely tell,' she said. 'And when you go to dinners, you can definitely see. We eat, like, an eighth of our meal. I know what's going on here.'
The doctors know they are privileged.
At first, Dr. Buse's health insurance paid for his Wegovy. But soon North Carolina stopped paying for obesity drugs for state employees, so he paid out of pocket. With a list price of $1,349 a month, it was a major expense.
Then, at a meeting in Europe, he asked a colleague to prescribe Wegovy for him and got a six-month supply. Dr. Buse was able to purchase Wegovy for a quarter of what it cost in the United States.
The doctors also know how to advocate for themselves and navigate the medical system better than many of their patients do.
Dr. McGuire's insurer initially declined to pay for his drugs. 'I had to appeal,' he said. 'I have a relationship with a primary care physician and know when to keep pushing.'
His insurer agreed to pay.
Dr. Gibson said that his insurer had paid without issue and that he wanted to discuss his decision to take Wegovy openly. (He recently switched to Lilly's Zepbound, also covered by his insurance, because it elicits an even greater weight loss.)
'A lot of people are of the mind-set that it is shameful, that it is cheating to use a drug,' Dr. Gibson said.
But the obesity drugs changed his life, he said: 'It's the greatest thing I ever did.'
And even Zepbound, powerful as it is, is just the beginning, Dr. Gibson said.
'There are 120 new agents coming along,' he noted, referring to drugs in clinical trials. 'I look forward to ones that may have even better safety and effectiveness.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide products, Wegovy (obesity) and Ozempic (diabetes). Building upon this success, NVO is developing several next-generation candidates in its pipeline, especially targeting the lucrative U.S. market. The most advanced candidate in Novo Nordisk's pipeline is CagriSema, a fixed-dose combination of a long-acting amylin analogue and Wegovy. CagriSema met the primary endpoint of statistically significant weight loss in two late-stage studies. The company is already planning its regulatory submission in 2026. Novo Nordisk is also developing an early-stage candidate, Amycretin, a unimolecular GLP-1 and amylin receptor agonist, which had outperformed Wegovy in a phase I study. Novo Nordisk has also been pursuing licensing deals and acquisitions to further expand its obesity pipeline. In 2023, it acquired Inversago Pharmaceuticals, which added a small-molecule oral CB1 inverse agonist, monlunabant, to its pipeline. Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, type II diabetes (T2D) and other cardiometabolic diseases. Eli Lilly LLY is NVO's fierce competitor in the obesity space, which markets its tirzepatide medicines as Mounjaro for T2D and Zepbound for obesity. Like NVO, LLY is also evaluating several next-generation weight loss candidates. Lilly recently reported first phase III success of its oral GLP-1 candidate, orforglipron, which showed significant weight reduction potential in the late-stage study. Regulatory filings for orforglipron are planned in 2025 and 2026. Several other companies, like Viking Therapeutics VKTX, are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. VKTX initiated a mid-stage study on the oral formulation of the candidate earlier this year and is on track to start the late-stage study on the subcutaneous version soon. Year to date, Novo Nordisk shares have plunged 15.5% compared with the industry's decline of 2.3%. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading above its 50-day moving average, but below its 200-day moving average. Image Source: Zacks Investment Research Novo Nordisk is trading at a premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 17.37 forward earnings, which is higher than 14.95 for the industry. However, the stock is trading much below its five-year mean of 29.25. Image Source: Zacks Investment Research Earnings estimates for 2025 have improved from $3.80 to $3.84 per share over the past 60 days. During the same time frame, Novo Nordisk's 2026 earnings per share estimates have improved from $4.60 to $4.64. Image Source: Zacks Investment Research The stock's return on equity on a trailing 12-month basis is 80.95%, which is higher than 33.56% for the large drugmaker industry, as seen in the chart below. Image Source: Zacks Investment Research Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research


New York Post
37 minutes ago
- New York Post
Doctors warn about ‘very real risks' of Ozempic ‘golden dosing' trend: ‘Recipes for disaster'
GLP-1 users might be jabbing for weight loss, but many are trying to combat cash loss by squeezing an extra dose out of their medication. The trend, dubbed 'golden dosing,' has been hyped by social media users as a way to get more bang for your buck. But doctors are warning it could be dangerous — and even set back your weight loss goals. 'Using a medication outside of its prescribed method is always risky — and in this case, especially unnecessary,' Dr. Michael Snyder, medical director of Bariatric Surgery at Rose Medical Center and an in-house expert at FuturHealth, told The Post. Advertisement 4 Surveys show that roughly 1 in 8 US adults have tried GLP-1 drugs. millaf – What is golden dosing? GLP-1 drugs like Ozempic, Mounjaro and Wegovy come in injectable pens that contain four doses, with each device lasting about a month. But some users have noticed that their pens often have leftover liquid after their final jab. This extra medication isn't a mistake. It's designed to allow for an initial flow check and to ensure that each of the four doses is accurate and complete. Advertisement Nevertheless, some TikTok users are extracting this leftover liquid with syringes and needles, using it as a fifth and final 'golden dose.' With out of pockets costs for these drugs sometimes topping $1,000 a pen, pulling out the extra medication has become a way to cut back a bit on exorbitant costs. But experts say the trend raises some major red flags. 'The 'golden dose' is more of a cost-saving strategy than one focused on safety and effectiveness,' Dr. Shiara Melissa Ortiz-Pujols, a bariatric surgeon at Northwell Health, told The Post. Advertisement 4 Typically, GLP-1 pens contain four doses. Fernanda – A dose of confusion GLP-1 pens deliver pre-measured doses that are carefully prescribed by healthcare providers based on factors like weight and health status. 'Any deviation — even what might seem like a 'small' one — can disrupt how your body responds,' Snyder warned. Advertisement GLP-1s are typically titrated, meaning the dosage is gradually increased over time to help the body adjust to the drug. 'As we increase the dose, we expect greater effectiveness, but we also face a higher risk of severe side effects,' Ortiz-Pujols explained. 4 Taking too much of the medication can lead to painful gastrointestinal effects. – Increasing your dose too quickly or taking inconsistent amounts week to week can worsen side effects, she said. It could also complicate your treatment plan, making it difficult for doctors to accurately track how your body is responding to the medications and make informed adjustments based on your personal needs, Snyder cautioned. From hack to hazard Attempting to recover leftover medication using a syringe also carries 'very real risks' for your health, Snyder said. Even minor miscalculations can lead to overdoses, triggering symptoms like nausea, vomiting and even pancreatitis. Advertisement 4 There's a major risk for bacterial growth if the syringe isn't completely sterile. Jo Panuwat D – On the flip side, underdosing can blunt the drug's effectiveness, resulting in weight regain and glucose instability. 'To put it simply, how comfortable would you feel using what you think is the 'right amount' of a blood pressure medication, a blood thinner, or a narcotic?' Snyder posed. 'All of those could be recipes for disaster. This situation is no different.' A hidden danger Advertisement The trend also poses a serious risk of infection. 'GLP-1 pens are designed to be used as a sealed system,' Snyder said. 'Using an external syringe breaks sterility, exposing the medication to bacteria during handling — even from clean-looking surfaces or hands.' This can lead to local infections at the injection site or even systemic infections, Snyder noted, emphasizing that the risk is particularly high for those who reuse syringes or directly touch the drug solution. 'There's no reliable way to make this DIY method safe,' Snyder said. 'That's why these pens are single-use and designed for highly controlled administration.'
Yahoo
an hour ago
- Yahoo
ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care
Novo Nordisk to present data from STEP UP trial on a higher dose of Wegovy® (semaglutide 7.2 mg) for those in need of greater weight loss Data will expand semaglutide evidence in both a clinical and real-world setting, including cardiometabolic and kidney health benefits for those with obesity and diabetes Novo Nordisk continues to pioneer obesity innovation, including presentation of full Phase 3 REDEFINE 1 and 2 trial results, providing insights into the transformational potential of CagriSema Bagsværd, Denmark, 10 June – Novo Nordisk today announced that new data from its industry-leading portfolio in metabolic and cardiovascular health will be showcased at the upcoming American Diabetes Association (ADA) 85th Scientific Sessions taking place in Chicago US, 20 – 23 June 2025. A total of 29 abstracts will be presented, including trials investigating the weight loss efficacy of higher dose Wegovy® (semaglutide 7.2 mg) in people with obesity (STEP UP) and those with obesity and type 2 diabetes (STEP UP T2D) as a new option for those in need of greater weight loss. New data will offer additional evidence of the broader cardiovascular and kidney health benefits of semaglutide for people with type 2 diabetes through analyses of the SOUL, STRIDE and FLOW trials, as well as insights from further real-world studies of semaglutide 2.4 mg. The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the transformational potential of this investigational medicine. Data will also be presented on pipeline candidate amycretin, demonstrating Novo Nordisk's commitment to obesity innovation and individualised healthcare solutions. On 22 June, Novo Nordisk will also host an R&D investor event on their metabolic and cardiovascular health portfolio to cover the science and abstracts presented at the congress. The event will be accessible via a live webcast on the Novo Nordisk investor website. 'Aiming to address individual needs and preferences for better health, we look forward to providing a higher dose of Wegovy® (semaglutide 7.2 mg) for people with obesity in need of more significant weight loss, alongside the broader health benefits seen with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'Semaglutide has shown comprehensive and disease-modifying effects across the metabolic and cardiovascular health spectrum, and the data presented at ADA 2025 for Wegovy®, Rybelsus®, and Ozempic® will add to this evidence base as we aspire to a future where semaglutide is a foundational therapy that can provide people with comprehensive protection, early enough to make a difference.' 'We recognise the complex interplay between cardiovascular and metabolic diseases, including type 2 diabetes and obesity, which require a personalised treatment approach,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'As we look to further build an impactful portfolio of medicines to address patient needs, our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support people living with serious chronic disease.' Novo Nordisk data overview at ADA 2025: ADA Scientific Sessions: Diabetes and peripheral artery disease—evolving role of GLP-1 RA and new insights from the STRIDE trial - Saturday 21 June; 13:30–15:00 CDT Efficacy and Safety of CagriSema 2.4 mg/2.4 mg in Adults with Overweight/Obesity—The REDEFINE 1 and REDEFINE 2 clinical trials - Sunday 22 June; 8:00–9:30 CDT SOUL trial—effects of oral semaglutide on cardiovascular (and other) outcomes in people with type 2 diabetes at high CV risk - Sunday 22 June; 16:30–18:00 CDT Novo Nordisk poster and oral presentations: Ozempic® (once-weekly semaglutide 1.0 mg) Impact of semaglutide on kidney, cardiovascular, and mortality outcomes by baseline BMI and weight loss in people with T2D and CKD: data from the FLOW Trial. Poster presentation (1971-LB poster) - Sunday 22 June; 12:30–13:30 CDT Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: a long-term cost effectiveness analysis based on FLOW. Poster presentation (782-P) - Sunday 22 June; 12:30–13:30 CDT Changes in clinical measures in US adults with type 2 diabetes (T2D) and chronic kidney disease (CKD) who received once-weekly (OW) semaglutide. Poster presentation (838-P) - Sunday 22 June; 12:30–13:30 CDT Changes in clinical measures among US adults with type 2 diabetes (T2D) and chronic kidney disease (CKD) receiving once-weekly semaglutide (sema OW) vs. oral antidiabetic medications (ADMs). Poster presentation (2005-LB poster) - Sunday 22 June; 12:30–13:30 CDT Effect of type 2 diabetes characteristics on semaglutide treatment in people with type 2 diabetes and peripheral artery disease: a post-hoc analysis of the STRIDE Trial. Oral presentation (291-OR) - Monday 23 June; 13:30–13:45 CDT Rybelsus® (once-daily oral semaglutide) Real-world impact of oral semaglutide (sema) alone and vs DPP-4is on weight, BMI and HbA1c outcomes in type 2 diabetes (T2D): an observational study (PAUSE). Poster presentation (732-P) - Sunday 22 June; 12:30–13:30 CDT Oral semaglutide and cardiovascular outcomes by baseline A1c and BMI in people with type 2 diabetes in the SOUL trial. Oral presentation (292-OR) - Monday 23 June; 13:45–14:00 CDT Wegovy® (once-weekly semaglutide 2.4 mg) Demographic and clinical characteristics associated with real-world persistence on semaglutide for weight management in the USA. Poster presentation (786-P) - Sunday 22 June; 12:30–13:30 CDT Two-year real-world effectiveness of semaglutide in patients with obesity or overweight. Poster presentation (1733-P) - Monday 23 June; 12:30–13:30 CDT Reduction of the 10-Year ASCVD risk in patients with overweight or obesity treated with semaglutide 2.4 mg in routine clinical care: a real-world study. Poster presentation (1734-P) - Monday 23 June; 12:30–13:30 CDT Once-weekly semaglutide 7.2 mg Efficacy and safety of semaglutide 7.2 mg in obesity: STEP UP trial. Poster presentation (1966-LB ePoster) - Saturday 21 June; 13:30–15:00 CDT Efficacy and safety of semaglutide 7.2 mg in obesity: STEP UP trial. Poster presentation (1966-LB poster) - Sunday 22 June; 12:30–13:30 CDT Efficacy and safety of semaglutide 7.2 mg in obesity and type 2 diabetes: STEP UP T2D trial. Poster presentation (1978-LB poster) - Sunday 22 June; 12:30–13:30 CDT CagriSema Effect of combined therapy with once-weekly subcutaneous cagrilintide 2.4 mg and semaglutide 2.4 mg (CagriSema) on energy intake, gastric emptying, and appetite in adults with overweight or obesity. Poster presentation (1969-LB poster) - Sunday 22 June; 12:30–13:30 CDT Diabetes, cagrisema-induced weight loss in diet-induced obese rats relies on preserved mitochondrial leak respiration in skeletal muscle. Poster presentation (1693-P) - Monday 23 June; 12:30–13:30 CDT Amycretin/amylin The amylin receptor selective agonist NN1213 reduces food intake and body weight in rats without decreasing calcium plasma levels. Oral presentation (86-OR) - Friday 20 June; 14:45–15:00 CDT Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist: results of a phase 1b/2a clinical trial. Poster presentation (2002-LB poster) - Sunday 22 June; 12:30–13:30 CDT Once-weekly insulin icodec Efficacy and hypoglycemia outcomes with once-weekly insulin icodec vs once-daily basal insulin in T2D by diabetes duration: ONWARDS 1–5. Poster presentation (816-P) - Saturday 21 June; 12:30– 13:30 CDT Efficacy and hypoglycemia outcomes with once-weekly insulin icodec vs once-daily basal insulin in T2D by baseline A1C: ONWARDS 1–5. Poster presentation (822-P) - Saturday 21 June; 12:30–13:30 CDT Efficacy and hypoglycemia outcomes with once-weekly insulin icodec vs once-daily basal insulin in T2D by baseline BMI: ONWARDS 1–5. Poster presentation (819-P) - Saturday 21 June; 12:30–13:30 CDT Once-weekly IcoSema CGM-derived model-based postprandial glucose with IcoSema vs other insulin regimens: a post hoc analysis of COMBINE 1 and 3. Poster presentation (815-P) - Saturday 21 June; 12:30–13:30 CDT A1C and hypoglycemia outcomes with once-weekly IcoSema vs comparators in T2D by kidney function. Poster presentation (804-P) - Saturday 21 June; 12:30–13:30 CDT CGM-based outcomes in adults with T2D receiving IcoSema vs comparators: post hoc analysis of COMBINE 1 and 3. Poster presentation (830-P) - Saturday 21 June; 12:30–13:30 CDT Comparison of characteristics among individuals with established vs newly diagnosed type 2 diabetes during ischemic stroke hospitalization – a retrospective cohort study. Poster presentation (1373-P) - Saturday 21 June; 12:30–13:30 CDT Digital Health Effect of telemonitoring using connected devices on insulin injection adherence in people living with T2D. Oral presentation (315-OR) - Monday 23 June; 13:30–13:45 CDT Tracking treatment outcomes using the semaglutide patient support solution app. Poster presentation (1098-P) - Sunday 22 June; 12:30–13:30 CDT General diabetes Prevalence and factors for treatment failure with sodium-glucose co-transporter 2 inhibitor (SGLT2i) in US adults with type 2 diabetes (T2D). Poster presentation (909-P) - Sunday 22 June; 12:30–13:30 CDT Macrovascular and microvascular complications in Medicare patients with type 2 diabetes and atherosclerotic cardiovascular disease from 2006-2021: incidence stratified by sex, age, and race/ethnicity. Poster presentation (1870-LB poster) - Sunday 22 June; 12:30–13:30 CDT Elevated body mass index at type 2 diabetes diagnosis is associated with increased risk of cardiovascular disease and kidney outcomes. Poster presentation (427-P) - Monday 23 June; 12:30–13:30 CDT General obesity Health utilities of people with obesity in Taiwan: a nationwide representative analysis. Publication Only (63-PUB) About semaglutideSemaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA), which mimics the effects of the naturally occurring hormone GLP-1. Semaglutide has been tested in several robust clinical development programmes and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease and other related cardiometabolic diseases. It has a cumulative exposure of over 33 million patient-years since 2018.1 Semaglutide is marketed under the brand names Wegovy® (once-weekly semaglutide 2.4 mg injection), Ozempic® (once-weekly semaglutide 1.0 mg injection), and Rybelsus® (once-daily oral semaglutide 14 mg). About CagriSemaOnce-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. The two molecules induce weight loss by reducing hunger, increasing feelings of fullness, thereby helping people eat less and reduce their calorie intake. About amycretinAmycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is developed for oral and subcutaneous administration. About once-weekly basal insulin icodec Insulin icodec is a once-weekly basal insulin analogue designed to cover the basal insulin requirements for a full week with a single subcutaneous injection. About once-weekly IcoSema Once-weekly IcoSema is a fixed-ratio combination of a once-weekly basal insulin icodec and once-weekly semaglutide (700U/2 mg per millilitre). IcoSema is titrated in the same way as insulin, with a maximum weekly dose of 350 dose steps (ie 350 U insulin icodec/1mg semaglutide). About Novo NordiskNovo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Ida Schaap Melvold +45 3077 5649 idmg@ Sina Meyer +45 3079 6656 azey@ Max Ung+45 3077 6414mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ 1 Novo Nordisk data on file. Attachment PR250610-ADA-Curtain-RaiserSign in to access your portfolio